Literature DB >> 15959877

The NAT1 C1095A polymorphism, maternal multivitamin use and smoking, and the risk of spina bifida.

Liselotte E Jensen1, Katy Hoess, Alexander S Whitehead, Laura E Mitchell.   

Abstract

BACKGROUND: The risk of having a child with a neural tube defect (NTD) can be reduced by maternal, periconceptional supplementation with folic acid, but the underlying folate-dependent protective mechanism remains unclear. N-acetyltransferase 1 is involved in acetylation of aromatic and heterocyclic amines and the catabolism of folates. Hence, functional polymorphisms in NAT1, the gene encoding N-acetyltransferase 1, are plausible risk factors for NTDs. Such variants could exert an influence on the risk of NTDs via their role in acetylation or folate catabolism and could act through the maternal or the embryonic genotype.
METHODS: NAT1 C1095A genotypes and information on maternal, periconceptional multivitamin use and smoking were obtained as part of a family-based study of spina bifida. Associations between spina bifida and the embryonic and maternal NAT1 C1095A genotypes, and potential NAT1 C1095A genotype-exposure interactions were evaluated using log-linear modeling.
RESULTS: The analyses provided no evidence that the embryonic or maternal NAT1 C1095 genotypes influence the risk of spina bifida independently, or through interactions with maternal use of multivitamins. There was evidence that the embryonic, and possibly the maternal, NAT1 C1095A genotype influence the risk of spina bifida via interactions with maternal smoking status.
CONCLUSIONS: The genotype for the NAT1 C1095A polymorphism does not appear to be an independent risk factor for spina bifida. However, the results of these analyses provide preliminary evidence that this polymorphism may be associated with the risk of spina bifida in the offspring of women who smoke during early pregnancy. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15959877     DOI: 10.1002/bdra.20143

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  15 in total

1.  NATb/NAT1*4 promotes greater arylamine N-acetyltransferase 1 mediated DNA adducts and mutations than NATa/NAT1*4 following exposure to 4-aminobiphenyl.

Authors:  Lori M Millner; Mark A Doll; Jian Cai; J Christopher States; David W Hein
Journal:  Mol Carcinog       Date:  2011-08-11       Impact factor: 4.784

2.  Phenotype of the most common "slow acetylator" arylamine N-acetyltransferase 1 genetic variant (NAT1*14B) is substrate-dependent.

Authors:  Lori M Millner; Mark A Doll; Jian Cai; J Christopher States; David W Hein
Journal:  Drug Metab Dispos       Date:  2011-10-18       Impact factor: 3.922

3.  Loss of function polymorphisms in NAT1 protect against spina bifida.

Authors:  Liselotte E Jensen; Karen Hoess; Laura E Mitchell; Alexander S Whitehead
Journal:  Hum Genet       Date:  2006-05-06       Impact factor: 4.132

4.  Genetic variation in biotransformation enzymes, air pollution exposures, and risk of spina bifida.

Authors:  Amy M Padula; Wei Yang; Kathleen Schultz; Fred Lurmann; S Katharine Hammond; Gary M Shaw
Journal:  Am J Med Genet A       Date:  2018-05       Impact factor: 2.802

5.  Functional effects of genetic polymorphisms in the N-acetyltransferase 1 coding and 3' untranslated regions.

Authors:  Yuanqi Zhu; J Christopher States; Yang Wang; David W Hein
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-02-02

Review 6.  Review on genetic variants and maternal smoking in the etiology of oral clefts and other birth defects.

Authors:  Min Shi; George L Wehby; Jeffrey C Murray
Journal:  Birth Defects Res C Embryo Today       Date:  2008-03

7.  Ocular defects associated with a null mutation in the mouse arylamine N-acetyltransferase 2 gene.

Authors:  Larissa Wakefield; Hilary Long; Nathan Lack; Edith Sim
Journal:  Mamm Genome       Date:  2007-05-09       Impact factor: 2.957

8.  Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1.

Authors:  Y Zhu; D W Hein
Journal:  Pharmacogenomics J       Date:  2007-10-02       Impact factor: 3.550

9.  Evaluation of 64 candidate single nucleotide polymorphisms as risk factors for neural tube defects in a large Irish study population.

Authors:  Tonia C Carter; Faith Pangilinan; James F Troendle; Anne M Molloy; Julia VanderMeer; Adam Mitchell; Peadar N Kirke; Mary R Conley; Barry Shane; John M Scott; Lawrence C Brody; James L Mills
Journal:  Am J Med Genet A       Date:  2010-12-10       Impact factor: 2.802

Review 10.  Genetics of human neural tube defects.

Authors:  Nicholas D E Greene; Philip Stanier; Andrew J Copp
Journal:  Hum Mol Genet       Date:  2009-10-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.